Warning letter
Skyless, LLC: warning letter of Jan 23, 2023
FDA warning letter 636200 · Division of Pharmaceutical Quality Operations II
Key facts
| Reference number | 636200 |
|---|---|
| Company | Skyless, LLC |
| Subject | CGMP/Finished Pharmaceuticals/Adulterated |
| Issue date | Jan 23, 2023 |
| Posted date | Feb 28, 2023 |
| Issuing office | Division of Pharmaceutical Quality Operations II |
| Product type | Drugs |
| CFR sections cited | 310.545, 201.128, 207.41, 211.22, 211.34, 330, 330.2, 201.15(c)(2), 211.22(d), 211.67(b), 211.84(d)(1), 211.100(a) and 2 more |
| Inspection city | Ponce |
| Inspection ZIP | 00780 |
| Inspection start date | May 2, 2022 |
| Letter on fda.gov | fda.gov |
At a glance
- 10–99 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: